Omeros Debuts With $68 Million IPO Despite Legal Hassles from Former CFO
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.